Initially, concerns on hyperkalemia emerged with the introduction of SGLT2 inhibitors into clinical practice [3], as patients with DM are more susceptible to hyperkalemia, specifically in the presence of renal dysfunction. This evidence concerns the gene SLC5A2 and diabetes mellitus.